| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to establish the useful biomarkers to detect early in the utero during pregnancy of human neural tube defect. There are many things to be prepared to start clinical studies. Due to the restriction of the special medium in Japan, we have to change the protocol about the medium to grow amniotic fluid stem cells. Amniomax II is useful medium using amniotic fluid stem cells in the world, also in Japan. Our study is on going to establish the novel in the utero therapy using small molecules to decrease the risks of neural tube defect by epigenetic mechanisms.
|
